Inspire Medical Systems, Inc. (INSP) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Inspire Medical Systems, Inc. (INSP) Healthcare & Pipeline Overview

Inspire Medical Systems, Inc. pioneers minimally invasive neurostimulation technology for obstructive sleep apnea (OSA) treatment. With a focus on the Inspire system, the company offers a novel alternative to traditional therapies, positioning itself in the growing market for OSA solutions and demonstrating strong profit and gross margins.

What Is the Investment Thesis for INSP?

Inspire Medical Systems presents a notable research candidate within the medical device sector, driven by its innovative neurostimulation technology for OSA treatment. The company's high gross margin of 85.8% indicates strong pricing power and efficient operations. A key value driver is the increasing adoption of the Inspire system as an alternative to traditional CPAP therapy. Growth catalysts include expanding market penetration in the US and international markets, as well as ongoing product development efforts. Potential risks include competition from established medical device companies and the need for continued regulatory approvals. The company's P/E ratio of 14.62 suggests a potentially undervalued stock relative to its earnings, making it an interesting prospect for investors seeking growth in the medical technology space.

Based on FMP financials and quantitative analysis

INSP Key Highlights

Market Cap of $1.97B reflects investor confidence in Inspire's growth potential in the medical device market.

• P/E ratio of 14.62 indicates a potentially undervalued stock relative to its earnings.
• Profit Margin of 14.3% demonstrates effective cost management and pricing strategy.
• Gross Margin of 85.8% showcases strong pricing power and efficient operations.
• Beta of 0.86 suggests lower volatility compared to the overall market, indicating a relatively stable investment.

Who Are INSP's Competitors?

INSP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are INSP's Key Strengths?

Innovative and minimally invasive technology.

• Strong clinical evidence and patient outcomes.
• High gross margin and profitability.
• Growing market for OSA treatment.

What Are INSP's Weaknesses?

Relatively high cost of the Inspire procedure.

• Limited awareness among patients and physicians.
• Dependence on reimbursement from insurance companies.
• Requires a surgical procedure for device implantation.

What Could Drive INSP Stock Higher?

Publication of new clinical data supporting the effectiveness of Inspire therapy (Q3 2026).

• Expansion of reimbursement coverage by major insurance providers.
• Increased awareness and adoption of Inspire therapy through marketing and education efforts.
• Launch of next-generation Inspire technology with enhanced features (2027).

What Are the Key Risks for INSP?

Competition from established medical device companies offering alternative OSA treatments.

• Changes in reimbursement policies affecting the affordability of the Inspire procedure.
• Product recalls or safety concerns related to the Inspire system.
• Dependence on physician training and expertise for successful implantation and programming of the Inspire device.

What Are the Growth Opportunities for INSP?

• Expansion into International Markets: Inspire has a significant opportunity to expand its market presence beyond the United States. The global market for OSA treatment is substantial, and many countries lack effective treatment options. By strategically entering new international markets, Inspire can tap into a large and underserved patient population. This expansion requires navigating regulatory approvals and establishing distribution networks, but the potential rewards are significant. The timeline for international expansion is ongoing, with a focus on key European and Asian markets.
• Development of Next-Generation Technology: Inspire is actively developing a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation. This next-generation technology has the potential to further improve the effectiveness and patient experience of Inspire therapy. Successful development and commercialization of this technology would solidify Inspire's position as a leader in OSA treatment. The timeline for this development is estimated at 3-5 years, with ongoing clinical trials and regulatory submissions.
• Increased Awareness and Adoption of Inspire Therapy: Many patients and physicians are still unaware of the Inspire system as a treatment option for OSA. By increasing awareness through marketing and education efforts, Inspire can drive greater adoption of its therapy. This includes targeting sleep specialists, primary care physicians, and patients directly. A successful awareness campaign would lead to increased referrals and a larger patient base. The timeline for this initiative is ongoing, with continuous efforts to reach new audiences.
• Strategic Partnerships with Healthcare Providers: Collaborating with hospitals, sleep clinics, and other healthcare providers can accelerate the adoption of Inspire therapy. By establishing strategic partnerships, Inspire can gain access to a wider network of patients and streamline the referral process. These partnerships can also involve training and education programs for healthcare professionals. The timeline for establishing these partnerships is ongoing, with a focus on key healthcare systems and institutions.
• Expansion into Adjacent Therapeutic Areas: While Inspire's primary focus is on OSA, its neurostimulation technology has potential applications in other therapeutic areas. Exploring these adjacent markets could open up new growth opportunities for the company. This requires research and development efforts to adapt the technology for different conditions. The timeline for this expansion is estimated at 5-7 years, with initial focus on areas such as snoring and upper airway resistance syndrome.

What Are INSP's Competitive Advantages?

• Proprietary neurostimulation technology protected by patents.
• Established brand reputation and clinical evidence supporting the effectiveness of Inspire therapy.
• High switching costs for patients who have already undergone the Inspire procedure.
• Strong relationships with sleep specialists and healthcare providers.

What Does INSP Do?

Inspire Medical Systems, Inc., founded in 2007 and headquartered in Golden Valley, Minnesota, is a medical technology company dedicated to transforming the treatment of obstructive sleep apnea (OSA). The company's flagship product, the Inspire system, represents a significant advancement in OSA therapy. Unlike traditional treatments like CPAP, Inspire is a minimally invasive neurostimulation technology that works inside the body with a small device placed during a same-day, outpatient procedure. This device delivers mild stimulation to key airway muscles, keeping the airway open during sleep. Inspire is commercially available in the United States and internationally. The company continues to innovate, developing a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire's focus on patient-centric solutions and technological innovation has established it as a key player in the medical device industry, specifically within the OSA treatment landscape. With a profit margin of 14.3% and a gross margin of 85.8%, the company showcases strong financial health.

What Products and Services Does INSP Offer?

• Develops and commercializes minimally invasive solutions for obstructive sleep apnea (OSA).
• Offers the Inspire system, a neurostimulation technology for moderate to severe OSA.
• Provides an alternative to traditional OSA treatments like CPAP.
• Focuses on improving patient compliance and outcomes in OSA therapy.
• Innovates in the field of neurostimulation for respiratory disorders.
• Offers a same-day, outpatient procedure for device implantation.

How Does INSP Make Money?

• Generates revenue from the sale of the Inspire system device.
• Provides training and support to physicians and healthcare providers.
• Secures reimbursement from insurance companies for the Inspire procedure.
• Expands market reach through direct sales and strategic partnerships.

What Industry Does INSP Operate In?

Inspire Medical Systems operates within the medical device industry, specifically targeting the obstructive sleep apnea (OSA) market. The OSA market is characterized by a large and growing patient population, driven by factors such as obesity and aging. Traditional treatments like CPAP machines have limitations in terms of patient compliance and effectiveness, creating an opportunity for innovative solutions like the Inspire system. The competitive landscape includes established medical device companies offering CPAP therapy and other OSA treatments. Inspire differentiates itself through its minimally invasive neurostimulation technology, providing an alternative for patients who are not well-suited for or compliant with CPAP therapy.

Who Are INSP's Key Customers?

• Patients with moderate to severe obstructive sleep apnea (OSA).
• Sleep specialists and ENT physicians who perform the Inspire procedure.
• Hospitals and sleep clinics that offer Inspire therapy.
• Insurance companies that reimburse for the Inspire procedure.

Company Profile

Inspire Medical Systems, Inc. operates in the Medical Devices industry within the Healthcare sector. It is headquartered in Golden Valley, United States.

Return on equity for Inspire Medical Systems, Inc. stands at 17.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 14.6%, showing how much profit it generates from its asset base. INSP trades at a trailing price-to-earnings ratio of 14.62, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 6.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.4%, the inverse of the P/E and a quick read on earnings relative to price.

INSP Valuation & Market Position

With a $1.97B market cap, Inspire Medical Systems, Inc. sits in the small-cap segment of the market. Analyst price targets span from $39.00 to $85.00, with a consensus of $60.30. At the current price of $68.12, that implies roughly 11% downside from the consensus target. Relative to its peer group, INSP's quantitative score of 97/100 is above the peer average of 65/100.

Quarterly Financial Performance: Inspire Medical Systems, Inc.

Revenue for Inspire Medical Systems, Inc. came in at $200.6M during Q2 FY2026, a 2.0% contraction versus the preceding quarter. The company recorded net income of $314K, with diluted EPS of $0.01. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, INSP averaged $1.15 in diluted EPS.

Inspire Medical Systems, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 13.43 places it in the safe zone, indicating low near-term bankruptcy risk.

Inspire Medical Systems, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 217.7% above estimates on average.

Over the past six months, Inspire Medical Systems, Inc. insiders filed 24 SEC Form 4 transactions — 6 sales and 18 purchases. On net that is roughly 38K shares acquired (about $176K) — insiders putting money in tends to read as conviction.

INSP Financials

INSP Latest News

INSP Analyst Consensus

INSP MoonshotScore

Latest Inspire Medical Systems, Inc. Analysis

INSP Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources